摘要
目的分析冠心病冠状动脉介入不同给药方案对患者血清炎性因子、冠脉血流的影响。方法选择2021年6月—2022年6月泰安市市立医院心内科、冠心病监护病房(coronary care unit,CCU)及重症监护室(intensive care unit,ICU)住院的急性冠脉综合征(acute coronary syndrome,ACS)并行经皮冠状动脉介入术(percutaneous coronary intervention,PCI)的100例患者为研究对象。根据时间来源分组,2021年6—12月的48例纳入对照组,2022年1—6月的52例纳入观察组。两组患者入院时均给予阿司匹林肠溶片,观察组在此基础上口服替格瑞洛,对照组在此基础上口服氢氯吡格雷。对比入院第1天及PCI术后第1天血清炎性因子(C反应蛋白、血清降钙素原及白介素-6)水平及冠脉血流指标(左前降支收缩期血流峰值、左前降支舒张期血流峰值、冠脉血流储备)。结果两组患者治疗前血清hs-CRP、PCT、IL-6水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者血清hs-CRP、PCT、IL-6水平(111.8±2.41)mg/L、(1.56±0.46)μg/L、(40.83±6.78)ng/L低于对照组,差异有统计学意义(t=143.082、5.306、3.679,P<0.05)。两组患者治疗前SPV、DPV、CFVR比较,差异无统计学意义(P>0.05);治疗后,观察组患者SPV、DPV、CFVR高于对照组,差异有统计学意义(t=4.189、33.520、5.021,P<0.05)。结论替格瑞洛在冠心病冠状动脉介入给药方案中更能够降低患者的血清炎性因子,提高患者的冠脉血流。
Objective To analyze the effects of different administration plans of coronary intervention on serum inflammatory factors and coronary blood flow in patients with coronary heart disease.Methods 100 patients with acute coronary syndrome(ACS)and percutaneous coronary intervention(PCI)admitted to the Cardiology Department,Coronary Care Unit(CCU),and Intensive Care Unit(ICU)of Tai'an Municipal Hospital from June 2021 to June 2022 were selected as the study subjects.According to the grouping of time sources,48 cases from June to December 2021 were included in the control group,and 52 cases from January to June 2022 were included in the observation group.Both groups of patients were treated with aspirin enteric coated tablets upon admission,while the observation group received oral tigrel on this basis,while the control group received oral hydrocclopidogrel on this basis.The levels of serum inflammatory factors(C-reactive protein,serum calcitonin and interleukin-6)and coronary flow indexes(systolic peak flow of left anterior descending artery,diastole peak flow of left anterior descending artery,coronary flow reserve)were compared on the first day of admission and the first day after PCI.Results There was no statistically significant difference in serum hs-CRP,PCT,and IL-6 levels between the two groups of patients before treatment(P>0.05);after treatment,the serum levels of hs-CRP,PCT,and IL-6 in the observation group were(111.8±2.41)mg/L,(1.56±0.46)μg/L,and(40.83±6.78)ng/L,and the difference was statistically significant(t=143.082,5.306,3.679,P<0.05).There was no statistically significant difference in the coronary blood flow indicators SPV,DPV,and CFVR between the two groups of patients before treatment(P>0.05);after treatment,the SPV,DPV,and CFVR in the observation group were higher than those in the control group,and the difference was statistically significant(t=4.189,33.520,5.021,P<0.05).Conclusion Ticagrelor in coronary artery intervention administration can reduce serum inflammatory factors and improve coronary blood flow in patients with coronary heart disease.
作者
黄强
王丽丽
张帅
陈霞
HUANG Qiang;WANG Lili;ZHANG Shuai;CHEN Xia(Department of Cardiology,Tai'an Municipal Hospital,Tai'an,Shandong Province,271000 China;Fourth Ward,Tai'an Rongjun Hospital,Tai'an,Shandong Province,271000 China;Sixth Ward,Tai'an Rongjun Hospital,Tai'an,Shandong Province,271000 China;Outpatient Department,Tai'an Rongjun Hospital,Tai'an,Shandong Province,271000 China)
出处
《系统医学》
2023年第4期5-8,共4页
Systems Medicine
基金
泰安市科技发展计划(2018009)。
关键词
冠心病
冠状动脉介入
不同给药方案
血清炎性因子
冠脉血流
Coronary heart disease
Coronary intervention
Different administration regimens
Serum inflammatory factors
Coronary blood flow
